GelTex To Discuss Anti-Obesity Collaboration With Roche, CEO Says
Executive Summary
GelTex could begin discussions with Roche on a development agreement to improve Roche's anti-obesity therapy Xenical (orlistat), GelTex CEO Mark Skaletsky told financial analysts at the Hambrecht & Quist Health Care Conference in San Francisco Jan. 12.